Resveratrol in medicinal chemistry: A critical review of its pharmacokinetics, drug-delivery, and membrane interactions

Current Medicinal Chemistry

Volumn 19, Issue 11, 2012, Pages 1663-1681

  Neves, A R ^a   Lucio M ^a   Lima, J L C ^a   Reis, S ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Drug delivery systems; Drug membrane interactions; Pharmacokinetics; Resveratrol

Indexed keywords

CYCLODEXTRIN; DNA POLYMERASE; FORKHEAD TRANSCRIPTION FACTOR; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; MEMBRANE PROTEIN; MICROSPHERE; MITOGEN ACTIVATED PROTEIN KINASE P38; NANOPARTICLE; OXIDOREDUCTASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P53; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; RESVERATROL; RIBONUCLEOTIDE REDUCTASE; SILENT INFORMATION REGULATOR PROTEIN 2; SIRTUIN 1; SOLID LIPID NANOPARTICLE; SUPEROXIDE DISMUTASE; SURVIVIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGY; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BRAIN ISCHEMIA; CARCINOGENESIS; CELL CYCLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CIS TRANS ISOMERISM; DERMATITIS; DNA DAMAGE; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG GLUCURONIDATION; DRUG INTERACTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; DYSLIPIDEMIA; ENCAPSULATION; ENZYME INHIBITION; EPILEPSY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GONORRHEA; HEART PROTECTION; HUMAN; HUNTINGTON CHOREA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; MICROENCAPSULATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARKINSON DISEASE; POLYGONUM CUSPIDATUM; RED WINE; REVIEW; THROMBOGENESIS; TINEA CAPITIS; TINEA PEDIS; TUMOR GROWTH; UPREGULATION; VERATRUM; YEAST CELL;

ANIMALS; ANTIOXIDANTS; CELL MEMBRANE; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; STILBENES;

EID: 84860540855     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799945085     Document Type: Review

References (331)

1. Goswami, S. K.; Das, D. K. Resveratrol and chemoprevention. Cancer Lett., 2009, 284 1, 1-6.
2. Fontecave, M.; Lepoivre, M.; Elleingand, E.; Gerez, C.; Guittet, O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. Febs Letters, 1998, 421 3, 277-279.
3. Saiko, P.; Szakmary, A.; Jaeger, W.; Szekeres, T. Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res.-Rev. Mutat. Res., 2008, 658(1-2), 68-94.
4. Szkudelska, K.; Szkudelski, T. Resveratrol, obesity and diabetes. Eur. J. Pharmacol., 2010, 635(1-3), 1-8.
5. Langcake, P.; Pryce, R. J. Production of resveratrol by Vitis-vinifera and other members of vitaceae as a response to infection or injury. Physiological Plant Pathology, 1976, 9 1, 77-86.
6. Soleas, G. J.; Diamandis, E. P.; Goldberg, D. M. Resveratrol: A molecule whose time has come? And gone? Clin. Biochem., 1997, 30 2, 91-113.
7. Douillet-Breuil, A. C.; Jeandet, P.; Adrian, M.; Bessis, N. Changes in the phytoalexin content of various Vitis spp. in response to ultraviolet C elicitation. J. Agric. Food Chem., 1999, 47 10, 4456-4461.
8. Adrian, M.; Jeandet, P.; Douillet-Breuil, A. C.; Tesson, L.; Bessis, R. Stilbene content of mature Vitis vinifera berries in response to UV-C elicitation. J. Agric. Food Chem., 2000, 48 12, 6103-6105.
9. Schubert, R.; Fischer, R.; Hain, R.; Schreier, P. H.; Bahnweg, G.; Ernst, D.; Sandermann, H. An ozone-responsive region of the grapevine resveratrol synthase promoter differs from the basal pathogen-responsive sequence. Plant Mol. Biol., 1997, 34 3, 417-426.
10. Adrian, M.; Jeandet, P.; Veneau, J.; Weston, L. A.; Bessis, R. Biological activity of resveratrol, a stilbenic compound from grapevines, against Botrytis cinerea, the causal agent for gray mold. J. Chem. Ecol., 1997, 23 7, 1689-1702.
11. Kundu, J. K.; Surh, Y. J. Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives. Cancer Lett., 2008, 269 2, 243-261.
12. Stervbo, U.; Vang, O.; Bonnesen, C. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem., 2007, 101 2, 449-457.
13. Bertelli, A. A. E.; Giovannini, L.; De Caterina, R.; Bernini, W.; Migliori, M.; Fregoni, M.; Bavaresco, L.; Bertelli, A. Antiplatelet activity of cisresveratrol. Drug Exp. Clin. Res, 1996, 22 2, 61-63.
14. Trela, B. C.; Waterhouse, A. L. Resveratrol: Isomeric molar absorptivities and stability. J. Agric. Food Chem., 1996, 44 5, 1253-1257.
15. Vian, M. A.; Tomao, V.; Gallet, S.; Coulomb, P. O.; Lacombe, J. M. Simple and rapid method for cis-and trans-resveratrol and piceid isomers determination in wine by high-performance liquid chromatography using Chromolith columns. J. Chromatogr. A, 2005, 1085 2, 224-229.
16. Richard, J. L. Coronary risk-factors - the french paradox. Arch. Mal. Coeur Vaiss., 1987, 80, 17-21.
17. Renaud, S.; Delorgeril, M.; Rylander, R.; Hennig, B.; Heimburger, D. The french paradox - dietary factors and cigarette smoking-related health risk. Ann. N. Y. Acad. Sci., 1993, 686, 299-309.
18. Nanji, A. A.; French, S. W. Alcoholic beverages and coronary heart-disease. Atherosclerosis, 1986, 60 2, 197-198.
19. Renaud, S.; Delorgeril, M. Wine, alcohol, platelets, and the french paradox for coronary heart-disease. Lancet, 1992, 339 8808, 1523-1526.
20. Criqui, M. H.; Ringel, B. L. Does diet or alcohol explain the french paradox. Lancet, 1994, 344(8939-4), 1719-1723.
21. Goldberg, D. M.; Hahn, S. E.; Parkes, J. G. Beyond alcohol - beverage consumption and cardiovascular mortality. Clin. Chim. Acta, 1995, 237(1-2), 155-187.
22. Whitehead, T. P.; Robinson, D.; Allaway, S.; Syms, J.; Hale, A. Effect of red wine ingestion on the antioxidant capacity of serum. Clin. Chem., 1995, 41 1, 32-35.
23. Fuhrman, B.; Lavy, A.; Aviram, M. Consumption of red wine with meals reduces the susceptibility of humam plasma and low-density-lipoprotein to lipid-peroxidation. Am. J. Clin. Nutr., 1995, 61 3, 549-554.
24. Kopp, P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur. J. Endocrinol., 1998, 138 6, 619-620.
25. Bertelli, A. A. A.; Das, D. K. Grapes, Wines, Resveratrol, and Heart Health. J. Cardiovasc. Pharmacol., 2009, 54 6, 468-476.
26. Jang, M. S.; Cai, E. N.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Beecher, C. W. W.; Fong, H. H. S.; Farnsworth, N. R.; Kinghorn, A. D.; Mehta, R. G.; Moon, R. C.; Pezzuto, J. M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275 5297, 218-220.
27. Dore, S. Unique properties of polyphenol stilbenes in the brain: More than direct antioxidant actions; Gene/protein regulatory activity. Neurosignals, 2005, 14(1-2), 61-70.
28. Olas, B.; Wachowicz, B. Resveratrol and vitamin C as antioxidants in blood platelets. Thromb. Res., 2002, 106 2, 143-148.
29. de la Lastral, C. A.; Villegas, I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Trans., 2007, 35, 1156-1160.
30. Fauconneau, B.; Waffo Teguo, P.; Huguet, F.; Barrier, L.; Decendit, A.; Merillon, J. M. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci., 1997, 61 21, 2103-2110.
31. Leonard, S. S.; Xia, C.; Jiang, B. H.; Stinefelt, B.; Klandorf, H.; Harris, G. K.; Shi, X. L. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun., 2003, 309 4, 1017-1026.
32. Shakibaei, M.; Csaki, C.; Nebrich, S.; Mobasheri, A. Resveratrol suppresses interleukin-1 beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: Potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem. Pharmacol., 2008, 76 11, 1426-1439.
33. Zhu, J.; Yong, W.; Wu, X. H.; Yu, Y.; Lv, J. H.; Liu, C. P.; Mao, X. D.; Zhu, Y. X.; Xu, K. F.; Han, X.; Liu, C. Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes. Biochem. Biophys. Res. Commun., 2008, 369 2, 471-477.
34. de la Lastra, C. A.; Villegas, I. Resveratrol as an anti-inflammatory and antiaging agent: Mechanisms and clinical implications. Mol. Nutr. Food Res., 2005, 49 5, 405-430.
35. Delmas, D.; Lancon, A.; Colin, D.; Jannin, B.; Latruffe, N. Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Curr. Drug Targets, 2006, 7 4, 423-442.
36. Signorelli, P.; Ghidoni, R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J. Nutr. Biochem., 2005, 16 8, 449-466.
37. Ulrich, S.; Wolter, F.; Stein, J. M. Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol. Nutr. Food Res., 2005, 49 5, 452-461.
38. Hudson, T. S.; Hartle, D. K.; Hursting, S. D.; Nunez, N. P.; Wang, T. T. Y.; Young, H. A.; Arany, P.; Green, J. E. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res., 2007, 67 17, 8396-8405.
39. Aziz, M. H.; Reagan-Shaw, S.; Wu, J. Q.; Longley, B. J.; Ahmad, N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? Faseb J., 2005, 19 6, 1193-+.
40. Atten, M. J.; Attar, B. M.; Milson, T.; Holian, O. Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem. Pharmacol., 2001, 62 10, 1423-1432.
41. El-Mowafy, A. M.; Alkhalaf, M. Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis, 2003, 24 5, 869-873.
42. Bhat, K. P. L.; Pezzuto, J. M., Cancer chemopreventive activity of resveratrol. In Alcohol and Wine in Health and Disease, Das, D. K.; Ursini, F., Eds. New York Acad Sciences: New York, 2002; Vol. 957, pp 210-229.
43. Savouret, J. F.; Quesne, M. Resveratrol and cancer: a review. Biomed. Pharmacother., 2002, 56 2, 84-87.
44. Aggarwal, B. B.; Bhardwaj, A.; Aggarwal, R. S.; Seeram, N. P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res., 2004, 24(5A), 2783-2840.
45. Choi, H. K.; Yang, J. W.; Kang, K. W. Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell. Cancer Lett., 2006, 242 2, 198-206.
46. Hsieh, T. C.; Wang, Z. R.; Hamby, C. V.; Wu, J. M. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem. Biophys. Res. Commun., 2005, 334 1, 223-230.
47. Joe, A. K.; Liu, H.; Suzui, M.; Vural, M. E.; Xiao, D. H.; Weinstein, I. B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin. Cancer Res., 2002, 8 3, 893-903.
48. Park, J. W.; Choi, Y. J.; Jang, M. A.; Lee, Y. S.; Jun, D. Y.; Suh, S. I.; Baek, W. K.; Suh, M. H.; Jin, I. N.; Kwon, T. K. Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett., 2001, 163 1, 43-49.
49. Howitz, K. T.; Bitterman, K. J.; Cohen, H. Y.; Lamming, D. W.; Lavu, S.; Wood, J. G.; Zipkin, R. E.; Chung, P.; Kisielewski, A.; Zhang, L. L.; Scherer, B.; Sinclair, D. A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425 6954, 191-196.
50. Wood, J. G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S. L.; Tatar, M.; Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 2004, 430 7000, 686-689.
51. Viswanathan, M.; Kim, S. K.; Berdichevsky, A.; Guarente, L. A role for SIR-2.1 regulation of ER stress response genes in determining C-elegans life span. Dev. Cell, 2005, 9 5, 605-615.
52. Valenzano, D. R.; Terzibasi, E.; Genade, T.; Cattaneo, A.; Domenici, L.; Cellerino, A. Resveratrol prolongs lifespan and retards the onset of agerelated markers in a short-lived vertebrate. Curr. Biol., 2006, 16 3, 296-300.
53. Harikumar, K. B.; Aggarwal, B. B. Resveratrol - A multitargeted agent for age-associated chronic diseases. Cell Cycle, 2008, 7 8, 1020-1035.
54. Parker, J. A.; Arango, M.; Abderrahmane, S.; Lambert, E.; Tourette, C.; Catoire, H.; Neri, C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nature Genet., 2005, 37 4, 349-350.
55. Bastianetto, S.; Zheng, W. H.; Quirion, R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br. J. Pharmacol., 2000, 131 4, 711-720.
56. Bradamante, S.; Barenghi, L.; Villa, A. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev., 2004, 22 3, 169-188.
57. Delmas, D.; Jannin, B.; Latruffe, N. Resveratrol: Preventing properties against vascular alterations and ageing. Mol. Nutr. Food Res., 2005, 49 5, 377-395.
58. Olas, B.; Wachowicz, B. Resveratrol, a phenolic antioxidant with effects on blood platelet functions. Platelets, 2005, 16 5, 251-260.
59. Rivera, L.; Moron, R.; Zarzuelo, A.; Galisteo, M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol., 2009, 77 6, 1053-1063.
60. Burstein, B.; Maguy, A.; Clement, R.; Gosselin, H.; Poulin, F.; Ethier, N.; Tardif, J. C.; Hebert, T. E.; Calderone, A.; Nattel, S. Effects of resveratrol (trans-3, 5, 4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J. Pharmacol. Exp. Ther., 2007, 323 3, 916-923.
61. Hung, L. M.; Chen, J. K.; Huang, S. S.; Lee, R. S.; Su, M. J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc. Res., 2000, 47 3, 549-555.
62. Das, D. K.; Maulik, N. Resveratrol in cardioprotection: A therapeutic promise of alternative medicine. Mol. Interv., 2006, 6 1, 36-47.
63. Pervaiz, S.; Holme, A. L. Resveratrol: Its Biologic Targets and Functional Activity. Antioxid. Redox Signal., 2009, 11 11, 2851-2897.
64. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Prabhu, V. V.; Allard, J. S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P. J.; Poosala, S.; Becker, K. G.; Boss, O.; Gwinn, D.; Wang, M. Y.; Ramaswamy, S.; Fishbein, K. W.; Spencer, R. G.; Lakatta, E. G.; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K.; de Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444 7117, 337-342.
65. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5 6, 493-506.
66. Gusman, J.; Malonne, H.; Atassi, G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis, 2001, 22 8, 1111-1117.
67. Kundu, J. K.; Surh, Y. J. Molecular basis of chemoprevention by resveratrol: NF-kappa B and AP-1 as potential targets. Mutat. Res.-Fundam. Mol. Mech. Mutagen., 2004, 555(1-2), 65-80.
68. Banerjee, S.; Bueso-Ramos, C.; Aggarwal, B. B. Suppression of 7, 12-dimethylbenz (a) anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappa B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 2002, 62 17, 4945-4954.
69. Sengottuvelan, M.; Viswanathan, P.; Nalini, N. Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1, 2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis, 2006, 27 5, 1038-1046.
70. Li, Z. G.; Hong, T.; Shimada, Y.; Komoto, I.; Kawabe, A.; Ding, Y.; Kaganoi, J.; Hashimoto, Y.; Imamura, M. Suppression of Nnitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis, 2002, 23 9, 1531-1536.
71. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357 9255, 539-545.
72. O'Byrne, K. J.; Dalgleish, A. Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer, 2001, 85 4, 473-483.
73. Whitcomb, D. C. Inflammation and cancer - V. Chronic pancreatitis and pancreatic cancer. Am. J. Physiol.-Gastroint. Liver Physiol., 2004, 287 2, G315-G319.
74. Itzkowitz, S. H.; Yio, X. Y. Inflammation and cancer - IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol.-Gastroint. Liver Physiol., 2004, 287 1, G7-G17.
75. Stojanovic, S.; Sprinz, H.; Brede, O. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogs in the radical liposome oxidation. Arch. Biochem. Biophys., 2001, 391 1, 79-89.
76. Subbaramaiah, K.; Chung, W. J.; Michaluart, P.; Telang, N.; Tanabe, T.; Inoue, H.; Jang, M. S.; Pezzuto, J. M.; Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 1998, 273 34, 21875-21882.
77. Szewczuk, L. M.; Forti, L.; Stivala, L. A.; Penning, T. M. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2 - A mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem., 2004, 279 21, 22727-22737.
78. Sgambato, A.; Ardito, R.; Faraglia, B.; Boninsegna, A.; Wolf, F. I.; Cittadini, A. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 2001, 496(1-2), 171-180.
79. Lanzilli, G.; Fuggetta, M. P.; Tricarico, M.; Cottarelli, A.; Serafino, A.; Falchetti, R.; Ravagnan, G.; Turriziani, M.; Adamo, R.; Franzese, O.; Bonmassar, E. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int. J. Oncol., 2006, 28 3, 641-648.
80. Della Ragione, F.; Cucciolla, V.; Borriello, A.; Della Pietra, V.; Racioppi, L.; Soldati, G.; Manna, C.; Galletti, P.; Zappia, V. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem. Biophys. Res. Commun., 1998, 250 1, 53-58.
81. Surh, Y. J.; Hurh, Y. J.; Kang, J. Y.; Lee, E.; Kong, G.; Lee, S. J. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett., 1999, 140(1-2), 1-10.
82. Dong, Z. G. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat. Res.-Fundam. Mol. Mech. Mutagen., 2003, 523, 145-150.
83. Elford, H. L.; Freese, M.; Passaman, E; Morris, H. P. Ribonucleotide reductase and cell proliferation. 1. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J. Biol. Chem., 1970, 245 20, 5228-&.
84. Locatelli, G. A.; Savio, M.; Forti, L.; Shevelev, I.; Ramadan, K.; Stivala, L. A.; Vannini, V.; Hubscher, U.; Spadari, S.; Maga, G. Inhibition of mammalian DNA polymerases by resveratrol: mechanism and structural determinants. Biochem. J., 2005, 389, 259-268.
85. Sun, N. J.; Woo, S. H.; Cassady, J. M.; Snapka, R. M. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J. Nat. Prod., 1998, 61 3, 362-366.
86. Stewart, J. R.; Ward, N. E.; Ioannides, C. G.; O'Brian, C. A. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry, 1999, 38 40, 13244-13251.
87. Rubiolo, J. A.; Mithieux, G.; Vega, F. V. Resveratrol protects primary rat hepatocytes against oxidative stress damage: Activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur. J. Pharmacol., 2008, 591(1-3), 66-72.
88. Kode, A.; Rajendrasozhan, S.; Caito, S.; Yang, S. R.; Megson, I. L.; Rahman, I. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am. J. Physiol.-Lung Cell. Mol. Physiol., 2008, 294 3, L478-L488.
89. Hebbar, V.; Shen, G. X.; Hu, R.; Kim, B. R.; Chen, C.; Korytko, P. J.; Crowell, J. A.; Levine, B. S.; Kong, A. N. T. Toxicogenomics of resveratrol in rat liver. Life Sci., 2005, 76 20, 2299-2314.
90. Hussain, S. P.; Harris, C. C. Inflammation and cancer: An ancient link with novel potentials. Int. J. Cancer, 2007, 121 11, 2373-2380.
91. Kundu, J. K.; Surh, Y. J. Breaking the relay in deregulated cellular signal transduction as a rationale for chemoprevention with anti-inflammatory phytochemicals. Mutat. Res.-Fundam. Mol. Mech. Mutagen., 2005, 591(1-2), 123-146.
92. Paceasciak, C. R.; Hahn, S.; Diamandis, E. P.; Soleas, G.; Goldberg, D. M. The red wine phenolics trans-resveratrol and quercetin block human plateletagregation and eicosanoid synthesis - implications for protection against coronary heart-disease. Clin. Chim. Acta, 1995, 235 2, 207-219.
93. Maccarrone, M.; Lorenzon, T.; Guerrieri, P.; Agro, A. F. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur. J. Biochem., 1999, 265 1, 27-34.
94. Martinez, J.; Moreno, J. J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol., 2000, 59 7, 865-870.
95. Manna, S. K.; Mukhopadhyay, A.; Aggarwal, B. B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol., 2000, 164 12, 6509-6519.
96. Holmes-McNary, M.; Baldwin, A. S. Chemopreventive properties of transresveratrol are associated with inhibition of activation of the I kappa B kinase. Cancer Res., 2000, 60 13, 3477-3483.
97. Schroder, K.; Hertzog, P. J.; Ravasi, T.; Hume, D. A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol., 2004, 75 2, 163-189.
98. Boscolo, P.; Del Signore, A.; Sabbioni, E.; Di Gioacchino, M.; Di Giampaolo, L.; Reale, M.; Conti, P.; Paganelli, R.; Giaccio, M. Effects of resveratrol on lymphocyte proliferation and cytokine release. Ann. Clin. Lab. Sci., 2003, 33 2, 226-231.
99. Gao, X. H.; Xu, Y. X.; Janakiraman, N.; Chapman, R. A.; Gautam, S. C. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem. Pharmacol., 2001, 62 9, 1299-1308.
100. Beaven, M. A.; Moore, J. P.; Smith, G. A.; Hesketh, T. R.; Metcalfe, J. C. The calcium signal and phosphatidylinositol breakdown in 2H3 cells. J. Biol. Chem., 1984, 259 11, 7137-7142.
101. Han, G.; Lu, S. L.; Li, A. G.; He, W.; Corless, C. L.; Kulesz-Martin, M.; Wang, X. J. Distinct mechanisms of TGF-beta (1)-mediated epithelial- tomesenchymal transition and metastasis during skin carcinogenesis. J. Clin. Invest., 2005, 115 7, 1714-1723.
102. Shaywitz, A. J.; Greenberg, M. E. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem., 1999, 68, 821-861.
103. Mitchell, S. H.; Zhu, W.; Young, C. Y. F. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res., 1999, 59 23, 5892-5895.
104. Damianaki, A.; Bakogeorgou, E.; Kampa, M.; Notas, G.; Hatzoglou, A.; Panagiotou, S.; Gemetzi, C.; Kouroumalis, E.; Martin, P. M.; Castanas, E. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J. Cell. Biochem., 2000, 78 3, 429-441.
105. Gautam, S. C.; Xu, Y. X.; Dumaguin, M.; Janakiraman, N.; Chapman, R. A. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant., 2000, 25 6, 639-645.
106. Pozo-Guisado, E.; Alvarez-Barrientos, A.; Mulero-Navarro, S.; Santiago-Josefat, B.; Fernandez-Salguero, P. M. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem. Pharmacol., 2002, 64 9, 1375-1386.
107. Schneider, Y.; Vincent, F.; Duranton, B.; Badolo, L.; Gosse, F.; Bergmann, C.; Seiler, N.; Raul, F. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett., 2000, 158 1, 85-91.
108. Zhou, H. B.; Yan, Y.; Sun, Y. N.; Zhu, J. R. Resveratrol induces apoptosis in human esophageal carcinoma cells. World J. Gastroenterol., 2003, 9 3, 408-411.
109. Reichard, P. Regulation of deoxyribotide synthesis. Biochemistry, 1987, 26 12, 3245-3248.
110. Alkhalaf, M.; Jaffal, S. Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: Novel cellular mechanisms involving the ERKs/p53 cascade. Free Radic. Biol. Med., 2006, 41 2, 318-325.
111. Huang, C. S.; Ma, W. Y.; Goranson, A.; Dong, Z. G. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis, 1999, 20 2, 237-242.
112. Hsieh, T. C.; Juan, G.; Darzynkiewicz, Z.; Wu, J. M. Resvesatrol increases nitric oxide synthase, induces accumulation of p53 and p21 (WAF1/CIP1) and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G (2). Cancer Res., 1999, 59 11, 2596-2601.
113. Hsieh, T. C.; Burfeind, P.; Laud, K.; Backer, J. M.; Traganos, F.; Darzynkiewicz, Z.; Wu, J. M. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int. J. Oncol., 1999, 15 2, 245-252.
114. Kuo, P. L.; Chiang, L. C.; Lin, C. C. Resveratrol-induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci., 2002, 72 1, 23-34.
115. Lin, H. Y.; Shih, A.; Davis, F. B.; Tang, H. Y.; Martino, L. J.; Bennett, J. A.; Davis, P. J. Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J. Urol., 2002, 168 2, 748-755.
116. She, Q. B.; Bode, A. M.; Ma, W. Y.; Chen, N. Y.; Dong, Z. G. Resveratrolinduced activation of p53 and apoptosis is mediated by extracellular-signalregulated protein kinases and p38 kinase. Cancer Res., 2001, 61 4, 1604-1610.
117. She, Q. B.; Huang, C. S.; Zhang, Y. G.; Dong, Z. G. Involvement of c-jun NH2-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol. Carcinog., 2002, 33 4, 244-250.
118. Shih, A.; Davis, F. B.; Lin, H. Y.; Davis, P. J. Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK-and p53-dependent mechanism. J. Clin. Endocrinol. Metab., 2002, 87 3, 1223-1232.
119. Soleas, G. J.; Goldberg, D. M.; Grass, L.; Levesque, M.; Diamandis, E. P. Do wine polyphenols modulate p53 gene expression in human cancer cell lines? Clin. Biochem., 2001, 34 5, 415-420.
120. Alkhalaf, M. Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein translation in T47D human breast cancer cells. Pharmacology, 2007, 80(2-3), 134-143.
121. Parekh, P.; Motiwale, L.; Naik, N.; Rao, K. V. K. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Experimental and Toxicologic Pathology, 2011, 63(1-2), 167-173.
122. Fulda, S.; Debatin, K. M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand induced apoptosis by the chemopreventive agent resveratrol. Cancer Res., 2004, 64 1, 337-346.
123. Altieri, D. C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell Biol., 2006, 18 6, 609-615.
124. Altieri, D. C. Molecular circuits of apoptosis regulation and cell division control: The survivin paradigm. J. Cell. Biochem., 2004, 92 4, 656-663.
125. Dorrie, J.; Gerauer, H.; Wachter, Y.; Zunino, S. J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res., 2001, 61 12, 4731-4739.
126. Tinhofer, I.; Bernhard, D.; Senfter, M.; Anether, G.; Loeffler, M.; Kroemer, G.; Kofler, R.; Csordas, A.; Greil, R. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. Faseb J., 2001, 15 7, 1613-+.
127. Marchetti, P.; Castedo, M.; Susin, S. A.; Zamzami, N.; Hirsch, T.; Macho, A.; Haeffner, A.; Hirsch, F.; Geuskens, M.; Kroemer, G. Mitochondrial permeability transition is a central coordinating event of apoptosis. J. Exp. Med., 1996, 184 3, 1155-1160.
128. Zheng, J. B.; Ramirez, V. D. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol., 2000, 130 5, 1115-1123.
129. Anekonda, T. S. Resveratrol - A boon for treating Alzheimer's disease? Brain Res. Rev., 2006, 52 2, 316-326.
130. Marambaud, P.; Zhao, H. T.; Davies, P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem., 2005, 280 45, 37377-37382.
131. Cohen, H. Y.; Miller, C.; Bitterman, K. J.; Wall, N. R.; Hekking, B.; Kessler, B.; Howitz, K. T.; Gorospe, M.; de Cabo, R.; Sinclair, D. A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science, 2004, 305 5682, 390-392.
132. Tissenbaum, H. A.; Guarente, L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature, 2001, 410 6825, 227-230.
133. You, H.; Mak, T. W. Crosstalk between p53 and FOXO transcription factors. Cell Cycle, 2005, 4 1, 37-38.
134. Borra, M. T.; Smith, B. C.; Denu, J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem., 2005, 280 17, 17187-17195.
135. Olas, B.; Wachowicz, B.; Szewczuk, J.; Saluk-Juszczak, J.; Kaca, W. The effect of resveratrol on the platelet secretory process induced by endotoxin and thrombin. Microbios, 2001, 105 410, 7-13.
136. Orsini, F.; Pelizzoni, F.; Verotta, L.; Aburjai, T.; Rogers, C. B. Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-Dglucopyranoside and related compounds. J. Nat. Prod., 1997, 60 11, 1082-1087.
137. Hattori, R.; Otani, H.; Maulik, N.; Das, D. K. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am. J. Physiol.-Heart Circul. Physiol., 2002, 282 6, H1988-H1995.
138. Wallerath, T.; Deckert, G.; Ternes, T.; Anderson, H.; Li, H.; Witte, K.; Forstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation, 2002, 106 13, 1652-1658.
139. Pendurthi, U. R.; Williams, J. T.; Rao, L. V. M. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells - A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler. Thromb. Vasc. Biol., 1999, 19 2, 419-426.
140. Smith, J. V.; Heilbronn, L. K.; Ravussin, E. Energy restriction and aging. Curr. Opin. Clin. Nutr. Metab. Care, 2004, 7 6, 615-622.
141. Holloszy, J. O.; Fontana, L. Caloric restriction in humans. Exp. Gerontol., 2007, 42 8, 709-712.
142. Lee, J. H.; Song, M. Y.; Song, E. K.; Kim, E. K.; Moon, W. S.; Han, M. K.; Park, J. W.; Kwon, K. B.; Park, B. H. Overexpression of SIRT1 Protects Pancreatic beta-Cells Against Cytokine Toxicity by Suppressing the Nuclear Factor-kappa B Signaling Pathway. Diabetes, 2009, 58 2, 344-351.
143. Hardie, D. G.; Pan, D. A. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans., 2002, 30, 1064-1070.
144. Szkudelska, K.; Nogowski, L.; Szkudelski, T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J. Steroid Biochem. Mol. Biol., 2009, 113(1-2), 17-24.
145. Hambrock, A.; Franz, C. B. D.; Hiller, S.; Grenz, A.; Ackermann, S.; Schulze, D. U.; Drews, G.; Osswald, H. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J. Biol. Chem., 2007, 282 5, 3347-3356.
146. Deng, J. Y.; Hsieh, P. S.; Huang, J. P.; Lu, L. S.; Hung, L. M. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes, 2008, 57 7, 1814-1823.
147. Palsamy, P.; Subramanian, S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem.-Biol. Interact., 2009, 179(2-3), 356-362.
148. Lee, S. K.; Mbwambo, Z. H.; Chung, H. S.; Luyengi, L.; Gamez, E. J. C.; Mehta, R. G.; Kinghorn, A. D.; Pezzuto, J. M. Evaluation of the antioxidant potential of natural products. Comb. Chem. High Throughput Screen, 1998, 1 1, 35-46.
149. Vastano, B. C.; Chen, Y.; Zhu, N. Q.; Ho, C. T.; Zhou, Z. Y.; Rosen, R. T. Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J. Agric. Food Chem., 2000, 48 2, 253-256.
150. Burns, J.; Yokota, T.; Ashihara, H.; Lean, M. E. J.; Crozier, A. Plant foods and herbal sources of resveratrol. J. Agric. Food Chem., 2002, 50 11, 3337-3340.
151. Pervaiz, S. Resveratrol: from grapevines to mammalian biology. Faseb J., 2003, 17 14, 1975-1985.
152. Sobolev, V. S.; Cole, R. J. trans-resveratrol content in commercial peanuts and peanut products. J. Agric. Food Chem., 1999, 47 4, 1435-1439.
153. Counet, C.; Callemien, D.; Collin, S. Chocolate and cocoa: New sources of trans-resveratrol and trans-piceid. Food Chem., 2006, 98 4, 649-657.
154. Rimando, A. M.; Kalt, W.; Magee, J. B.; Dewey, J.; Ballington, J. R. Resveratrol, pterostilbene, and piceatannol in Vaccinium berries. J. Agric. Food Chem., 2004, 52 15, 4713-4719.
155. Hurst, W. J.; Glinski, J. A.; Miller, K. B.; Apgar, J.; Davey, M. H.; Stuart, D. A. Survey of the trans-resveratrol and trans-piceid content of cocoacontaining and chocolate products. J. Agric. Food Chem., 2008, 56 18, 8374-8378.
156. Wang, Y.; Catana, F.; Yang, Y. N.; Roderick, R.; van Breemen, R. B. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J. Agric. Food Chem., 2002, 50 3, 431-435.
157. Sanders, T. H.; McMichael, R. W.; Hendrix, K. W. Occurrence of resveratrol in edible peanuts. J. Agric. Food Chem., 2000, 48 4, 1243-1246.
158. Bolling, B. W.; McKay, D. L.; Blumberg, J. B. The phytochemical composition and antioxidant actions of tree nuts. Asia Pacific Journal of Clinical Nutrition, 2010, 19 1, 117-123.
159. Siemann, E. H.; Creasy, L. L. Concentration of the phytoalexin resveratrol in wine. Am. J. Enol. Vitic., 1992, 43 1, 49-52.
160. Creasy, L. L.; Coffee, M. Phytoalexin production potential of grape berries. J. Am. Soc. Hortic. Sci., 1988, 113 2, 230-234.
161. Fornara, V.; Onelli, E.; Sparvoli, F.; Rossoni, M.; Aina, R.; Marino, G.; Citterio, S. Localization of stilbene synthase in Vitis vinifera L. during berry development. Protoplasma, 2008, 233(1-2), 83-93.
162. Wang, W.; Tang, K.; Yang, H. R.; Wen, P. F.; Zhang, P.; Wang, H. L.; Huang, W. D. Distribution of resveratrol and stilbene synthase in young grape plants (Vitis vinifera L. cv. Cabernet Sauvignon) and the effect of UVC on its accumulation. Plant Physiol. Biochem., 2010, 48(2-3), 142-152.
163. Smith, C. J. Accumulation of phytoalexins: Defence mechanism and stimulus response system. New Phytol., 1996, 132 1, 1-45.
164. Goldberg, D. M.; Tsang, E.; Karumanchiri, A.; Diamandis, E. P.; Soleas, G.; Ng, E. Method to assay the concentrations of phenolic constituents of biological interest in wines. Anal. Chem., 1996, 68 10, 1688-1694.
165. Guerrero, R. F.; Garcia-Parrilla, M. C.; Puertas, B.; Cantos-Villar, E. Wine, Resveratrol and Health: a Review. Nat. Prod. Commun., 2009, 4 5, 635-658.
166. Goldberg, D. M.; Ng, E.; Karumanchiri, A.; Yan, J.; Diamandis, E. P.; Soleas, G. J. Assay of resveratrol glucosides and isomers in wine by directinjection high-performance liquid-chromatography. J. Chromatogr. A, 1995, 708 1, 89-98.
167. Goldberg, D. M.; Garovic Kocic, V.; Diamandis, E. P.; Pace Asciak, C. R. Wine: Does the colour count? Clin. Chim. Acta, 1996, 246(1-2), 183-193.
168. Martinez-Ortega, M. V.; Carcia-Parrilla, M. C.; Troncoso, A. M. Resveratrol content in wines and musts from the south of Spain. Nahr.-Food, 2000, 44 4, 253-256.
169. Roldan, A.; Palacios, V.; Caro, I.; Perez, L. Resveratrol content of Palomino fino grapes: Influence of vintage and fungal infection. J. Agric. Food Chem., 2003, 51 5, 1464-1468.
170. Gambuti, A.; Strollo, D.; Ugliano, M.; Lecce, L.; Moio, L. trans-Resveratrol, quercetin, (+)-catechin, and (-)-epicatechin content in south Italian monovarietal wines: Relationship with maceration time and marc pressing during winemaking. J. Agric. Food Chem., 2004, 52 18, 5747-5751.
171. Jeandet, P.; Bessis, R.; Maume, B. F.; Meunier, P.; Peyron, D.; Trollat, P. Effect of enological practices on the resveratrol isomer content of wine. J. Agric. Food Chem., 1995, 43 2, 316-319.
172. Mattivi, F.; Reniero, F.; Korhammer, S. Isolation, characterization, and evolution in red wine vinification of resveratrol monomers. J. Agric. Food Chem., 1995, 43 7, 1820-1823.
173. Moreno-Labanda, J. F.; Mallavia, R.; Perez-Fons, L.; Lizama, V.; Saura, D.; Micol, V. Determination of piceid and resveratrol in Spanish wines deriving from Monastrell (Vitis vinifera L.) grape variety. J. Agric. Food Chem., 2004, 52 17, 5396-5403.
174. Shin, S. Y.; Han, N. S.; Park, Y. C.; Kim, M. D.; Seo, J. H. Production of resveratrol from p-coumaric acid in recombinant Saccharomyces cerevisiae expressing 4-coumarate:coenzyme A ligase and stilbene synthase genes. Enzyme Microb. Technol., 2011, 48 1, 48-53.
175. Limem, I.; Guedonc, E.; Hehn, A.; Bourgaud, F.; Ghedira, L. C.; Engasser, J. M.; Ghoul, M. Production of phenylpropanoid compounds by recombinant microorganisms expressing plant-specific biosynthesis genes. Process Biochem., 2008, 43 5, 463-479.
176. Becker, J. V. W.; Armstrong, G. O.; Van der Merwe, M. J.; Lambrechts, M. G.; Vivier, M. A.; Pretorius, I. S. Metabolic engineering of Saccharomyces cerevisiae for the synthesis of the wine-related antioxidant resveratrol. FEMS Yeast Res., 2003, 4 1, 79-85.
177. Beekwilder, J.; Wolswinkel, R.; Jonker, H.; Hall, R.; de Vos, C. H. R.; Bovy, A. Production of resveratrol in recombinant microorganisms. Appl. Environ. Microbiol., 2006, 72 8, 5670-5672.
178. Jeandet, P.; Douillt-Breuil, A. C.; Bessis, R.; Debord, S.; Sbaghi, M.; Adrian, M. Phytoalexins from the vitaceae: biosynthesis, phytoalexin gene expression in transgenic plants, antifungal activity, and metabolism. J. Agric. Food Chem., 2002, 50 10, 2731-2741.
179. Colin, D.; Lancon, A.; Delmas, D.; Lizard, G.; Abrossinow, J.; Kahn, E.; Jannin, B.; Latruffe, N. Antiproliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analyses. Biochimie, 2008, 90(11-12), 1674-1684.
180. Moran, B. W.; Anderson, F. P.; Devery, A.; Cloonan, S.; Butler, W. E.; Varughese, S.; Draper, S. M.; Kenny, P. T. M. Synthesis, structural characterisation and biological evaluation of fluorinated analogs of resveratrol. Bioorg Med Chem, 2009, 17 13, 4510-22.
181. Cai, Y. J.; Wei, Q. Y.; Fang, J. G.; Yang, L.; Liu, Z. L.; Wyche, J. H.; Han, Z. Y. The 3, 4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities. Anticancer Res., 2004, 24(2B), 999-1002.
182. Matsuoka, A.; Takeshita, K.; Furuta, A.; Ozaki, M.; Fukuhara, K.; Miyata, N. The 4'-hydroxy group is responsible for the in vitro cytogenetic activity of resveratrol. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 2002, 521(1-2), 29-35.
183. Wieder, T.; Prokop, A.; Bagci, B.; Essmann, F.; Bernicke, D.; Schulze-Osthoff, K.; Dorken, B.; Schmalz, H. G.; Daniel, P. T.; Henze, G. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia, 2001, 15 11, 1735-1742.
184. Murias, M.; Handler, N.; Erker, T.; Pleban, K.; Ecker, G.; Saiko, P.; Szekeres, T.; Jager, W. Resveratrol analogs as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem., 2004, 12 21, 5571-5578.
185. Wolter, F.; Clausnitzer, A.; Akoglu, B.; Stein, J. Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J. Nutr., 2002, 132 2, 298-302.
186. Potter, G. A.; Patterson, L. H.; Wanogho, E.; Perry, P. J.; Butler, P. C.; Ijaz, T.; Ruparelia, K. C.; Lamb, J. H.; Farmer, P. B.; Stanley, L. A.; Burke, M. D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYPIBI. Br. J. Cancer, 2002, 86 5, 774-778.
187. Hung, L. M.; Su, M. J.; Chu, W. K.; Chiao, C. W.; Chan, W. F.; Chen, J. K. The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy. Br. J. Pharmacol., 2002, 135 7, 1627-1633.
188. Murias, M.; Jager, W.; Handler, N.; Erker, T.; Horvath, Z.; Szekeres, T.; Nohl, H.; Gille, L. Antioxidant prooxidant and cytotoxic activity of hydroxylated resveratrol analogs: structure-activity relationship. Biochem. Pharmacol., 2005, 69 6, 903-912.
189. Horvath, Z.; Murias, M.; Saiko, P.; Erker, T.; Handler, N.; Madlener, S.; Jaeger, W.; Grusch, M.; Fritzer-Szekeres, M.; Krupitza, G.; Szekeres, T. Cytotoxic and biochemical effects of 3, 3', 4, 4', 5, 5'-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. Exp. Hematol., 2006, 34 10, 1377-1384.
190. Roberti, M.; Pizzirani, D.; Simoni, D.; Rondanin, R.; Baruchello, R.; Bonora, C.; Buscemi, F.; Grimaudo, S.; Tolomeo, M. Synthesis and biological evaluation of resveratrol and analogs as apoptosis-inducing agents. J. Med. Chem., 2003, 46 16, 3546-3554.
191. Rimando, A. M.; Cuendet, M.; Desmarchelier, C.; Mehta, R. G.; Pezzuto, J. M.; Duke, S. O. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analog of resveratrol. J. Agric. Food Chem., 2002, 50 12, 3453-3457.
192. Tolomeo, M.; Grimaudo, S.; Di Cristina, A.; Roberti, M.; Pizzirani, D.; Meli, M.; Dusonchet, L.; Gebbia, N.; Abbadessa, V.; Crosta, L.; Barucchello, R.; Grisolia, G.; Invidiata, F.; Simoni, D. Pterostilbene and 3'- hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Int. J. Biochem. Cell Biol., 2005, 37 8, 1709-1726.
193. Fragopoulou, E.; Nomikos, T.; Karantonis, H. C.; Apostolakis, C.; Pliakis, E.; Samiotaki, M.; Panayotou, G.; Antonopoulou, S. Biological activity of acetylated phenolic compounds. J. Agric. Food Chem., 2007, 55 1, 80-89.
194. Piver, B.; Berthou, F.; Dreano, Y.; Lucas, D. Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci., 2003, 73 9, 1199-1213.
195. Billard, C.; Izard, J. C.; Roman, V.; Kern, C.; Mathiot, C.; Mentz, F.; Kolb, J. P. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk. Lymphoma, 2002, 43 10, 1991-2002.
196. Quiney, C.; Dauzonne, D.; Kern, C.; Fourneron, J. D.; Izard, J. C.; Mohammad, R. M.; Kolb, J. P.; Billard, C. Flavones and polyphenols inhibit the NO pathway during apoptosis of leukemia B-cells. Leuk. Res., 2004, 28 8, 851-861.
197. Ohyama, M.; Tanaka, T.; Ito, T.; Iinuma, M.; Bastow, K. F.; Lee, K. H. Antitumor agents 200. Cytotoxicity of naturally occurring resveratrol oligomers and their acetate derivatives. Bioorg. Med. Chem. Lett., 1999, 9 20, 3057-3060.
198. Lancon, A.; Delmas, D.; Osman, H.; Thenot, J. P.; Jannin, B.; Latruffe, N. Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem. Biophys. Res. Commun., 2004, 316 4, 1132-1137.
199. Han, Y. S.; Bastianetto, S.; Dumont, Y.; Quirion, R. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J. Pharmacol. Exp. Ther., 2006, 318 1, 238-245.
200. Kimura, Y.; Okuda, H. Effects of naturally occurring stilbene glucosides from medicinal plants and wine, on tumour growth and lung metastasis in Lewis lung carcinoma-bearing mice. J. Pharm. Pharmacol., 2000, 52 10, 1287-1295.
201. Romero-Perez, A. I.; Ibern-Gomez, M.; Lamuela-Raventos, R. M.; de la Torre-Boronat, M. C. Piceid, the major resveratrol derivative in grape juices. J. Agric. Food Chem., 1999, 47 4, 1533-1536.
202. Arichi, H.; Kimura, Y.; Okuda, H.; Baba, K.; Kozawa, M.; Arichi, S. Effects of stilbene components of the roots of Polygonum-cuspidatum sieb et zucc on lipid-metabolism. Chem. Pharm. Bull., 1982, 30 5, 1766-1770.
203. Kimura, Y.; Okuda, H.; Arichi, S. Effects of stilbenes on arachidonate metabolism in leukocytes. Biochimica Et Biophysica Acta, 1985, 834 2, 275-278.
204. Bertelli, A. A. E.; Giovannini, L.; Stradi, R.; Urien, S.; Tillement, J. P.; Bertelli, A. Kinetics of trans-and cis-resveratrol (3, 4', 5-trihydroxystilbene) after red wine oral administration in rats. Int. J. Clin. Pharmacol. Res., 1996, 16(4-5), 77-81.
205. Bertelli, A.; Bertelli, A. A. E.; Gozzini, A.; Giovannini, L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drug Exp. Clin. Res, 1998, 24 3, 133-138.
206. Bertelli, A. A. E.; Giovannini, L.; Stradi, R.; Bertelli, A.; Tillement, J. P. Plasma, urine and tissue levels of trans-and cis-resveratrol (3, 4', 5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int. J. Tissue React.-Exp. Clin. Asp., 1996, 18(2-3), 67-71.
207. Juan, M. E.; Lamuela-Raventos, R. M.; de la Torre-Boronat, M. C.; Planas, J. M. Determination of trans-resveratrol in plasma by HPLC. Anal. Chem., 1999, 71 3, 747-750.
208. Soleas, G. J.; Angelini, M.; Grass, L.; Diamandis, E. P.; Goldberg, D. M., Absorption of trans-resveratrol in Rats. In Flavonoids and Other Polyphenols, Academic Press Inc: San Diego, 2001; Vol. 335, pp 145-154.
209. Asensi, M.; Medina, I.; Ortega, A.; Carretero, J.; Bano, M. C.; Obrador, E.; Estrela, J. M. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med., 2002, 33 3, 387-398.
210. Marier, J. F.; Vachon, P.; Gritsas, A.; Zhang, J.; Moreau, J. P.; Ducharme, M. P. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther., 2002, 302 1, 369-373.
211. Juan, M. E.; Buenafuente, J.; Casals, I.; Planas, J. M. Plasmatic levels of trans-resveratrol in rats. Food Res. Int., 2002, 35(2-3), 195-199.
212. Vitrac, X.; Desmouliere, A.; Brouillaud, B.; Krisa, S.; Deffieux, G.; Barthe, N.; Rosenbaum, J.; Merillon, J. M. Distribution of C-14-trans- resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci., 2003, 72 20, 2219-2233.
213. Meng, X. F.; Maliakal, P.; Lu, H.; Lee, M. J.; Yang, C. S. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J. Agric. Food Chem., 2004, 52 4, 935-942.
214. Sale, S.; Verschoyle, R. D.; Boocock, D.; Jones, D. J. L.; Wilsher, N.; Ruparelia, K. C.; Potter, G. A.; Farmer, P. B.; Steward, W. P.; Gescher, A. J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analog trans 3, 4, 5, 4'-tetramethoxystilbene. Br. J. Cancer, 2004, 90 3, 736-744.
215. Niles, R. M.; Cook, C. P.; Meadows, G. G.; Fu, Y. M.; McLaughlin, J. L.; Rankin, G. O. Resveratrol is rapidly metabolized in athymic (Nu/Nu) mice and does not inhibit human melanoma xenograft tumor growth. J. Nutr., 2006, 136 10, 2542-2546.
216. Goldberg, D. A.; Yan, J.; Soleas, G. J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem., 2003, 36 1, 79-87.
217. Walle, T.; Hsieh, F.; DeLegge, M. H.; Oatis, J. E.; Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32 12, 1377-1382.
218. Vitaglione, P.; Sforza, S.; Galaverna, G.; Ghidini, C.; Caporaso, N.; Vescovi, P. P.; Fogliano, V.; Marchelli, R. Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res., 2005, 49 5, 495-504.
219. Boocock, D. J.; Faust, G. E. S.; Patel, K. R.; Schinas, A. M.; Brown, V. A.; Ducharme, M. P.; Booth, T. D.; Crowell, J. A.; Perloff, M.; Gescher, A. J.; Steward, W. P.; Brenner, D. E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev., 2007, 16 6, 1246-1252.
220. Boocock, D. J.; Patel, K. R.; Faust, G. E. S.; Normolle, D. P.; Marczylo, T. H.; Crowell, J. A.; Brenner, D. E.; Booth, T. D.; Gescher, A.; Steward, W. P. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr. B, 2007, 848 2, 182-187.
221. Gescher, A. J.; Steward, W. P. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiol. Biomarkers Prev., 2003, 12 10, 953-957.
222. Kaldas, M. I.; Walle, U. K.; Walle, T. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J. Pharm. Pharmacol., 2003, 55 3, 307-312.
223. Maier-Salamon, A.; Hagenauer, B.; Wirth, M.; Gabor, F.; Szekeres, T.; Jager, W. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm. Res., 2006, 23 9, 2107-2115.
224. Wenzel, E.; Soldo, T.; Erbersdobler, H.; Somoza, V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res., 2005, 49 5, 482-494.
225. Wenzel, E.; Somoza, V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res., 2005, 49 5, 472-481.
226. Miksits, M.; Maier-Salamon, A.; Aust, S.; Thalhammer, T.; Reznicek, G.; Kunert, O.; Haslinger, E.; Szekeres, T.; Jaeger, W. Sulfation of resveratrol in human liver: Evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica, 2005, 35 12, 1101-1119.
227. Shu, X.-H.; Li, H.; Sun, Z.; Wu, M.-L.; Ma, J.-X.; Wang, J.-M.; Wang, Q.; Sun, Y.; Fu, Y.-S.; Chen, X.-Y.; Kong, Q.-Y.; Liu, J. Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem Pharmacol, 2010, 79 10, 1516-25.
228. Khan, M. A.; Muzammil, S.; Musarrat, J. Differential binding of tetracyclines with serum albumin and induced structural alterations in drugbound protein. Int. J. Biol. Macromol., 2002, 30 5, 243-249.
229. Belguendouz, L.; Fremont, L.; Linard, A. Resveratrol inhibits metal iondependent and independent peroxidation of porcine low-density lipoproteins. Biochem. Pharmacol., 1997, 53 9, 1347-1355.
230. Jannin, B.; Menzel, M.; Berlot, J. P.; Delmas, D.; Lancon, A.; Latruffe, N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem. Pharmacol., 2004, 68 6, 1113-1118.
231. Lu, Z.; Zhang, Y. Y.; Liu, H.; Yuan, J. L.; Zheng, Z. L.; Zou, G. L. Transport of a cancer chemopreventive polyphenol, resveratrol: Interaction with serum albumin and hemoglobin. J. Fluoresc., 2007, 17 5, 580-587.
232. Glatz, J. F. C.; vander Vusse, G. J. Cellular fatty acid-binding proteins: Their function and physiological significance. Prog. Lipid. Res., 1996, 35 3, 243-282.
233. Williams, L. D.; Burdock, G. A.; Edwards, J. A.; Beck, M.; Bausch, J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem. Toxicol., 2009, 47 9, 2170-2182.
234. Santner, S. J.; Feil, P. D.; Santen, R. J. In situ estrogen production via the estrone sulfatase pathway in breast-tumors - relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab., 1984, 59 1, 29-33.
235. Pacifici, G. M. Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: a review of the literature. Int. J. Clin. Pharmacol. Ther., 2004, 42 9, 488-495.
236. Schmitt, E.; Lehmann, L.; Metzler, M.; Stopper, H. Hormonal and genotoxic activity of resveratrol. Toxicol. Lett., 2002, 136 2, 133-142.
237. Levi, F.; Pasche, C.; Lucchini, F.; Ghidoni, R.; Ferraroni, M.; La Vecchia, C. Resveratrol and breast cancer risk. Eur. J. Cancer Prev., 2005, 14 2, 139-142.
238. Wang, Q.; Xu, J. F.; Rottinghaus, G. E.; Simonyi, A.; Lubahn, D.; Sun, G. Y.; Sun, A. Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res., 2002, 958 2, 439-447.
239. Athar, M.; Back, J. H.; Tang, X.; Kim, K. H.; Kopelovich, L.; Bickers, D. R.; Kim, A. L. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol., 2007, 224 3, 274-283.
240. Juan, M. E.; Wenzel, U.; Daniel, H.; Planas, J. M. Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J. Agric. Food Chem., 2008, 56 12, 4813-4818.
241. Jang, M. H.; Piao, X. L.; Kim, H. Y.; Cho, E. J.; Baek, S. H.; Kwon, S. W.; Park, J. H. Resveratrol oligomers from Vitis amurensis attenuate betaamyloidinduced oxidative stress in PC12 cells. Biol. Pharm. Bull., 2007, 30 6, 1130-1134.
242. Lopez-Nicolas, J. M.; Nunez-Delicado, E.; Perez-Lopez, A. J.; Barrachina, A. C.; Cuadra-Crespo, P. Determination of stoichiometric coefficients and apparent formation constants for beta-cyclodextrin complexes of transresveratrol using reversed-phase liquid chromatography. J. Chromatogr. A, 2006, 1135 2, 158-165.
243. Fremont, L. Minireview - Biological effects of resveratrol. Life Sci., 2000, 66 8, 663-673.
244. Schrooyen, P. M. M.; van der Meer, R.; De Kruif, C. G. Microencapsulation: its application in nutrition. Proc. Nutr. Soc., 2001, 60 4, 475-479.
245. Shahidi, F.; Han, X. Q. Encapsulation of food ingredients. Crit. Rev. Food Sci. Nutr., 1993, 33 6, 501-547.
246. Nelson, G. Application of microencapsulation in textiles. Int. J. Pharm., 2002, 242(1-2), 55-62.
247. Gouin, S. Microencapsulation: industrial appraisal of existing technologies and trends. Trends Food Sci. Technol., 2004, 15(7-8), 330-347.
248. Kabanov, A. V.; Gendelman, H. E. Nanomedicine in the diagnosis and therapy of neuro degenerative disorders. Prog. Polym. Sci., 2007, 32(8-9), 1054-1082.
249. Muller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50 1, 161-177.
250. Marcato, P. D.; Duran, N. New aspects of nanopharmaceutical delivery systems. J. Nanosci. Nanotechnol., 2008, 8 5, 2216-2229.
251. Das, S.; Ng, K. Y. Resveratrol-Loaded Calcium-Pectinate Beads: Effects of Formulation Parameters on Drug Release and Bead Characteristics. J. Pharm. Sci., 2009, 99 2, 840-860.
252. Lu, X.; Ji, C.; Xu, H.; Li, X.; Ding, H.; Ye, M.; Zhu, Z.; Ding, D.; Jiang, X.; Ding, X.; Guo, X. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int J Pharm, 2009, 375(1-2), 89-96.
253. Teskac, K.; Kristl, J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm., 2010, 390 1, 61-69.
254. Caddeo, C.; Teskac, K.; Sinico, C.; Kristl, J. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int. J. Pharm., 2008, 363(1-2), 183-191.
255. Das, S.; Ng, K. Y. Colon-specific delivery of resveratrol: optimization of multi-particulate calcium-pectinate carrier. Int J Pharm, 2010, 385(1-2), 20-8.
256. Das, S.; Ng, K. Y. Impact of glutaraldehyde on in vivo colon-specific release of resveratrol from biodegradable pectin-based formulation. J Pharm Sci, 2010, 99 12, 4903-16.
257. Das, S.; Ng, K. Y.; Ho, P. C. Formulation and optimization of zinc-pectinate beads for the controlled delivery of resveratrol. AAPS PharmSciTech, 2010, 11 2, 729-42.
258. Das, S.; Chaudhury, A.; Ng, K. Y. Preparation and evaluation of zinc-pectinchitosan composite particles for drug delivery to the colon: Role of chitosan in modifying in vitro and in vivo drug release. Int. J. Pharm., 2011, 406(1-2), 11-20.
259. Das, S.; Ng, K. Y.; Ho, P. C. Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaraldehyde as the hardening agent for colonic-specific delivery of resveratrol: In vitro and in vivo evaluations. J. Drug Target., 2011, 19 6, 446-457.
260. Ansari, K. A.; Vavia, P. R.; Trotta, F.; Cavalli, R. Cyclodextrin-Based Nanosponges for Delivery of Resveratrol: In vitro Characterisation, Stability, Cytotoxicity and Permeation Study. AAPS PharmSciTech, 2011, 12 1, 279-286.
261. Shi, G. R.; Rao, L. Q.; Yu, H. Z.; Xiang, H.; Yang, H.; Ji, R. Stabilization and encapsulation of photosensitive resveratrol within yeast cell. Int. J. Pharm., 2008, 349(1-2), 83-93.
262. Nam, J. B.; Ryu, J. H.; Kim, J. W.; Chang, I. S.; Suh, K. D. Stabilization of resveratrol immobilized in monodisperse cyano-functionalized porous polymeric microspheres. Polymer, 2005, 46 21, 8956-8963.
263. Shao, J.; Li, X.; Lu, X.; Jiang, C.; Hu, Y.; Li, Q.; You, Y.; Fu, Z. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf B Biointerfaces, 2009, 72 1, 40-7.
264. Coimbra, M.; Isacchi, B.; van Bloois, L.; Torano, J. S.; Ket, A.; Wu, X. J.; Broere, F.; Metselaar, J. M.; Rijcken, C. J. F.; Storm, G.; Bilia, R.; Schiffelers, R. M. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int. J. Pharm., 2011, 416 2, 433-442.
265. Fang, J. Y.; Hung, C. F.; Liao, M. H.; Chien, C. C. A study of the formulation design of acoustically active lipospheres as carriers for drug delivery. Eur. J. Pharm. Biopharm., 2007, 67 1, 67-75.
266. Shi, G.; Rao, L.; Yu, H.; Xiang, H.; Yang, H.; Ji, R. Stabilization and encapsulation of photosensitive resveratrol within yeast cell. Int J Pharm, 2008, 349(1-2), 83-93.
267. Duzgunes, N.; Nir, S. Mechanisms and kinetics of liposome-cell interactions. Adv. Drug Deliv. Rev., 1999, 40(1-2), 3-18.
268. Kristl, J.; Volk, B.; Gasperlin, M.; Sentjurc, M.; Jurkovic, P. Effect of colloidal carriers on ascorbyl palmitate stability. Eur. J. Pharm. Sci., 2003, 19 4, 181-189.
269. Sentjurc, M.; Kristl, J.; Abramovic, Z., Transport of liposome-entrapped substances into skin as measured by electron paramagnetic resonance oximetry in vivo. In Liposomes, Pt D, Elsevier Academic Press Inc: San Diego, 2004; Vol. 387, pp 267-287.
270. Padamwar, M. N.; Pokharkar, V. B. Development of vitamin loaded topical liposomal formulation using factorial design approach: Drug deposition and stability. Int. J. Pharm., 2006, 320(1-2), 37-44.
271. Manconi, M.; Isola, R.; Falchi, A. M.; Sinico, C.; Fadda, A. M. Intracellular distribution of fluorescent probes delivered by vesicles of different lipidic composition. Colloid Surf. B-Biointerfaces, 2007, 57 2, 143-151.
272. Hung, C. F.; Chen, J. K.; Liao, M. H.; Lo, H. M.; Fang, J. Y. Development and evaluation of emulsion-liposome blends for resveratrol delivery. J. Nanosci. Nanotechnol., 2006, 6(9-10), 2950-2958.
273. Budai, M.; Szabo, Z.; Zimmer, A.; Szogyi, M.; Grof, P. Studies on molecular interactions between nalidixic acid and liposomes. Int. J. Pharm., 2004, 279(1-2), 67-79.
274. Li, X. L.; Lie, R. T.; Qian, X. P.; Ding, Y. T.; Tu, Y. X.; Guo, R.; Hu, Y.; Jiang, X. Q.; Guo, W. H.; Liu, B. R. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur. J. Pharm. Biopharm., 2008, 70 3, 726-734.
275. Liu, B. R.; Yang, M.; Li, X. L.; Qian, X. P.; Shen, Z. T.; Ding, Y. T.; Yu, L. X. Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer. J. Pharm. Sci., 2008, 97 8, 3170-3181.
276. Shao, J. F.; Li, X. L.; Lu, X. W.; Jiang, C.; Hu, Y.; Li, Q. P.; You, Y. P.; Fu, Z. Enhanced growth inhibition effect of Resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloid Surf. B-Biointerfaces, 2009, 72 1, 40-47.
277. Ahlin, P.; Sentjurc, M.; Strancar, J.; Kristl, J. Location of lipophilic substances and ageing of solid lipid nanoparticles studied by EPR. STP Pharma Sci., 2000, 10 2, 125-132.
278. Matthaeus, C.; Kale, A.; Chernenko, T.; Torchilin, V.; Diem, M. New ways of imaging uptake and intracellular fate of liposomal drug carrier systems inside individual cells, based on Raman microscopy. Mol. Pharm., 2008, 5 2, 287-293.
279. Almeida, P. F. F.; Pokorny, A.; Hinderliter, A. Thermodynamics of membrane domains. Biochim. Biophys. Acta-Biomembr., 2005, 1720(1-2), 1-13.
280. Peetla, C.; Labhasetwar, V. Biophysical characterization of nanoparticleendothelial model cell membrane interactions. Mol. Pharm., 2008, 5 3, 418-429.
281. Muller, R. H.; Radtke, M.; Wissing, S. A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 2002, 54, S131-S155.
282. Kristl, J.; Teskac, K.; Milek, M.; Mlinaric-Rascan, I. Surface active stabilizer Tyloxapol in colloidal dispersions exerts cytostatic effects and apoptotic dismissal of cells. Toxicol. Appl. Pharmacol., 2008, 232 2, 218-225.
283. Cai, Y.; Gaffney, S. H.; Lilley, T. H.; Magnolato, D.; Martin, R.; Spencer, C. M.; Haslam, E. Polyphenol interactions. 4. Model studies with caffeine and cyclodextrins. J. Chem. Soc.-Perkin Trans., 2, 1990, (12), 2197-2209.
284. Lucas-Abellan, C.; Fortea, I.; Lopez-Nicolas, J. M.; Nunez-Delicado, E. Cyclodextrins as resveratrol carrier system. Food Chem., 2007, 104 1, 39-44.
285. Buschmann, H. J.; Schollmeyer, E. Applications of cyclodextrins in cosmetic products: A review. J. Cosmet. Sci., 2002, 53 3, 185-191.
286. Loftsson, T.; Brewster, M. E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci., 1996, 85 10, 1017-1025.
287. Szejtli, J. Medicinal applications of cyclodextrins. Medicinal Research Reviews, 1994, 14 3, 353-386.
288. Mura, P.; Faucci, M. T.; Parrini, P. L.; Furlanetto, S.; Pinzauti, S. Influence of the preparation method on the physicochemical properties of ketoprofencyclodextrin binary systems. Int. J. Pharm., 1999, 179 1, 117-128.
289. Castillo, J. A.; Palomo-Canales, J.; Garcia, J. J.; Lastres, J. L.; Bolas, F.; Torrado, J. J. Preparation and characterization of albendazole betacyclodextrin complexes. Drug Development and Industrial Pharmacy, 1999, 25 12, 1241-1248.
290. Mura, P.; Adragna, E.; Rabasco, A. M.; Moyano, J. R.; Perez-Martinez, J. I.; Arias, M. J.; Gines, J. M. Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin systems. Drug Development and Industrial Pharmacy, 1999, 25 3, 279-287.
291. Lutka, A. Investigation of interaction of promethazine with cyclodextrins. Acta poloniae pharmaceutica, 2002, 59 1, 45-51.
292. Nagase, Y.; Hirata, M.; Wada, K.; Arima, H.; Hirayama, F.; Irie, T.; Kikuchi, M.; Uekama, K. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether beta-cyclodextrin. Int. J. Pharm., 2001, 229(1-2), 163-172.
293. Jain, A. C.; Adeyeye, M. C. Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether beta-cyclodextrins (SBE) and danazol-SBE inclusion complexes. Int. J. Pharm., 2001, 212 2, 177-186.
294. Challa, R.; Ahuja, A.; Ali, J.; Khar, R. K. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech, 2005, 6 (2).
295. Trotta, F.; Cavalli, R. Characterization and Applications of New Hyper-Cross-Linked Cyclodextrins. Composite Interfaces, 2009, 16 1, 39-48.
296. Cavalli, R.; Trotta, F.; Tumiatti, W. Cyclodextrin-based nanosponges for drug delivery. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2006, 56(1-2), 209-213.
297. Bishop, J. R. P.; Nelson, G.; Lamb, J. Microencapsulation in yeast cells. J. Microencapsul., 1998, 15 6, 761-773.
298. Blanquet, S.; Garrait, G.; Beyssac, E.; Perrier, C.; Denis, S.; Hebrard, G.; Alric, M. Effects of cryoprotectants on the viability and activity of freeze dried recombinant yeasts as novel oral drug delivery systems assessed by an artificial digestive system. Eur. J. Pharm. Biopharm., 2005, 61(1-2), 32-39.
299. Blanquet, S.; Marol-Bonnin, S.; Beyssac, E.; Pompon, D.; Renaud, M.; Alric, M. The 'biodrug' concept: an innovative approach to therapy. Trends Biotechnol., 2001, 19 10, 393-400.
300. Zlotnik, H.; Fernandez, M. P.; Bowers, B.; Cabib, E. Saccharomycescerevisiae mannoproteins form an external cell-wall layer that determines wall porosity. J. Bacteriol., 1984, 159 3, 1018-1026.
301. Scherrer, R.; Louden, L.; Gerhardt, P. Porosity of yeast-cell wall and membrane. J. Bacteriol., 1974, 118 2, 534-540.
302. Dardelle, G.; Normand, V.; Steenhoudt, M.; Bouquerand, P. E.; Chevalier, M.; Baumgartner, P. Flavour-encapsulation and flavour-release performances of a commercial yeast-based delivery system. Food Hydrocolloids, 2007, 21(5-6), 953-960.
303. Friend, D. R. New oral delivery systems for treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev., 2005, 57 2, 247-265.
304. Grant, G. T.; Morris, E. R.; Rees, D. A.; Smith, P. J. C.; Thom, D. Biological interactions between polysaccharides and divalent cations - egg box model. Febs Letters, 1973, 32 1, 195-198.
305. Sriamornsak, P. Effect of calcium concentration, hardening agent and drying condition on release characteristics of oral proteins from calcium pectinate gel beads. Eur. J. Pharm. Sci., 1999, 8 3, 221-227.
306. Maestrelli, F.; Zerrouk, N.; Cirri, M.; Mennini, N.; Mura, P. Microspheres for colonic delivery of ketoprofen-hydroxypropyl-beta-cyclodextrin complex. Eur. J. Pharm. Sci., 2008, 34 1, 1-11.
307. Maestrelli, F.; Cirri, M.; Corti, G.; Mennini, N.; Mura, P. Development of enteric-coated calcium pectinate microspheres intended for colonic drug delivery. Eur. J. Pharm. Biopharm., 2008, 69 2, 508-518.
308. Zheng, J. B.; Ramirez, V. D. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem. Biophys. Res. Commun., 1999, 261 2, 499-503.
309. Teisseyre, A.; Michalak, K. Inhibition of the activity of human lymphocyte Kv1.3 potassium channels by resveratrol. J. Membr. Biol., 2006, 214 3, 123-129.
310. Garcia-Garcia, J.; Micol, V.; de Godos, A.; Gomez-Fernandez, J. C. The cancer chemopreventive agent resveratrol is incorporated into model membranes and inhibits protein kinase C alpha activity. Arch. Biochem. Biophys., 1999, 372 2, 382-388.
311. Nabekura, T.; Kamiyama, S.; Kitagawa, S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun., 2005, 327 3, 866-870.
312. Ferreira, M. J. U.; Duarte, N.; Gyemant, N.; Radics, R.; Cherepnev, G.; Varga, A.; Molnar, J. Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Anticancer Res., 2006, 26(5A), 3541-3546.
313. Wu, C. P.; Calcagno, A. M.; Hladky, S. B.; Ambudkar, S. V.; Barrand, M. A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). Febs J., 2005, 272 18, 4725-4740.
314. Cooray, H. C.; Janvilisri, T.; van Veen, H. W.; Hladky, S. B.; Barrand, M. A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun., 2004, 317 1, 269-275.
315. Wesolowska, O.; Wisniewski, J.; Duarte, N.; Ferreira, M. J. U.; Michalak, K. Inhibition of MRP1 transport activity by phenolic and terpenic compounds isolated from Euphorbia species. Anticancer Res., 2007, 27(6B), 4127-4133.
316. Fabris, S.; Momo, F.; Ravagnan, G.; Stevanato, R. Antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles and monolamellar liposomes. Biophys. Chem., 2008, 135(1-3), 76-83.
317. Tsuchiya, H.; Nagayama, M.; Tanaka, T.; Furusawa, M.; Kashimata, M.; Takeuchi, H. Membrane-rigidifying effects of anti-cancer dietary factors. Biofactors, 2002, 16(3-4), 45-56.
318. Sarpietro, M. G.; Spatafora, C.; Tringali, C.; Micieli, D.; Castelli, F. Interaction of resveratrol and its trimethyl and triacetyl derivatives with biomembrane models studied by differential scanning calorimetry. J. Agric. Food Chem., 2007, 55 9, 3720-3728.
319. Wesolowska, O.; Kuzdzal, M.; Skrancar, J.; Michalak, K. Interaction of the chemopreventive agent resveratrol and its metabolite, piceatannol, with model membranes. Biochim. Biophys. Acta-Biomembr., 2009, 1788 9, 1851-1860.
320. Chalpin, D. B.; Kleinfeld, A. M. Interaction of fluorescence quenchers with the normal-(9-anthroyloxy) fatty-acid membrane probes. Biochimica Et Biophysica Acta, 1983, 731 3, 465-474.
321. Brittes, J.; Lucio, M.; Nunes, C.; Lima, J.; Reis, S. Effects of resveratrol on membrane biophysical properties: relevance for its pharmacological effects. Chem. Phys. Lipids, 2010, 163 8, 747-754.
322. Klausner, R. D.; Kleinfeld, A. M.; Hoover, R. L.; Karnovsky, M. J. Lipid domains in membranes - evidence derived from structural perturbations induced by free fatty-acids and lifetime heterogeneity analysis. J. Biol. Chem., 1980, 255 4, 1286-1295.
323. Seddon, J. M. Structure of the inverted hexagonal (HII) phase, and nonlamellar phase-transitions of lipids. Biochimica Et Biophysica Acta, 1990, 1031 1, 1-69.
324. Epand, R. M. Relationship of phospholipid hexagonal phases to biological phenomena. Biochem. Cell Biol., 1990, 68 1, 17-23.
325. Cullis, P. R.; Dekruijff, B. Lipid polymorphism and the functional roles of lipids in biological-membranes. Biochimica Et Biophysica Acta, 1979, 559 4, 399-420.
326. Israelachvili, J. N.; Marcelja, S.; Horn, R. G. Physical principles of membrane organization. Q. Rev. Biophys., 1980, 13 2, 121-200.
327. Zidovetzki, R. Membrane properties and the activation of protein kinase C and phospholipase A (2). In Lipid Polymorphism and Membrane Properties, Academic Press Inc: San Diego, 1997; Vol. 44, pp 255-283.
328. Epand, R. M.; Lester, D. S. The role of membrane biophysical properties in the regulation of protein-kinase-C activity. Trends Pharmacol. Sci., 1990, 11 8, 317-320.
329. Epand, R. M.; Epand, R. F.; Lancaster, C. R. D. Modulation of the bilayer to hexagonal phase-transition of phosphatidylethanolamines by acylglycerols. Biochimica Et Biophysica Acta, 1988, 945 2, 161-166.
330. Epand, R. M. The relationship between the effects of drugs on bilayer stability and on protein-kinase-C activity. Chem.-Biol. Interact., 1987, 63 3, 239-247.
331. Epand, R. M.; Stafford, A. R.; Cheetham, J. J.; Bottega, R.; Ball, E. H. The relationship between the bilayer to haxagonal phase-transition temperature in membranes and protein kinase-C activity. Biosci. Rep., 1988, 8 1, 49-54.